At the forefront of innovation, the actors within BioAlps have an impressive track record of original thinking and bringing products to the market. Did you know that coronary stents were first developed in this region? Or that the first new molecule to halt the progression of multiple sclerosis to reach the market in many years was developed here?

As the life science industry becomes ever more sophisticated, it is increasingly interacting with sectors outside its traditional franchise such as fine chemicals, micro- and nanotechnology, semiconductors, information technology and agriculture. Recombinant DNA technology has provided almost unlimited quantities of proteins. The advances in particle science are delivering fine particles that can be used for drug delivery. Mechanical devices are being developed with the advances in engineering and IT technology.

Teams in BioAlps are developing more convergent technologies, at the intersection between biochemistry, engineering, biomaterials, medicine, biology, IT, microtechnology and nanotechnology. A wide array of bioconvergent research and development is looking at integrating a diagnosis, a product comprised of one or more regulated components, i.e. drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically or otherwise combined or mixed or produced as a single entity. High precision tools are increasingly important to the life science industry; Western Switzerland is uniquely placed to merge different disciplines to achieve greater performance.

Collaborations can be set up easily and quickly for researchers and companies alike. Products and applications in micro- and nanotechnologies, microelectronics, systems engineering, microrobotics, photonics, information and communication technologies are being developed. Innovative adaptive microfluidics technology and high tech automation systems are being used for a wide variety of applications, from drug discovery to consumer diagnostics.

For more information on the academic institutions within the cluster, click here. For more information on the companies in the cluster, please visit our database

Find an actor

ILMAC Lausanne 201803.10.2018

ILMAC Lausanne is the new platform for the chemical & life sciences community. The event will take place on 3 and 4...

Addex Pharma - recoit un financement de 1,2 M£

Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn